Industry veteran joins Auxilium Pharmaceuticals
Adrian Adams succeeds Armando Anido at the US firm
Adams has more than 30 years of experience in the pharmaceutical industry, most recently serving as chairman and ceo of Neurologix, a biotechnology company engaged in the development of gene therapies for disorders of the brain and central nervous system. Prior to that, he was president and ceo of Inspire Pharmaceuticals, where he oversaw the development and commercialisation of prescription pharmaceutical products and led the company through a strategic acquisition by Merck & Co.
Before joining Inspire, Adams was president and ceo of Sepracor until its acquisition by Dainippon Sumitomo Pharma Co in 2010. Prior to this, he was president and ceo of Kos Pharmaceuticals from 2002 until the company was acquired by Abbott Laboratories in 2006.
Adams has also held general management and senior international and national marketing positions at Novartis, SmithKline Beecham and ICI (now part of AstraZeneca).
You may also like
Regulatory
![Early phase analytical strategy for biosimilars in a shifting regulatory landscape]()
Early phase analytical strategy for biosimilars in a shifting regulatory landscape
As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Pharmaceutical
![Formulation freedom in clinical development: Why Fill2Weight matters]()
Formulation freedom in clinical development: Why Fill2Weight matters
As drug discovery accelerates, especially for poorly soluble small‑molecule compounds, formulation teams increasingly modify particle size, morphology and structure to improve dissolution in the body. This is precisely where 3P innovation’s proprietary Fill2Weight Gravimetric Powder Filler becomes a game‑changer
Research & Development
![Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline]()
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline
The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline risk in at-risk older adults during a three-year period
Pharmaceutical
![Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate]()
Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate
The agreement will expand Teva’s biosimilars pipeline, with the company securing exclusive commercialisation rights for Polpharma Biologics’ proposed ocrelizumab biosimilar across key global markets
Pharmaceutical
![Pouching solutions for sterile and moisture-sensitive devices]()
Pouching solutions for sterile and moisture-sensitive devices
Sterile pouch loading and sealing is far more complex than a conventional packaging operation: When the pouch itself becomes the primary sterile barrier (and the product is filled aseptically) the packaging process must be engineered with the same level of care as the filling operation itself
